Compare · LTRN vs SLRX
LTRN vs SLRX
Side-by-side comparison of Lantern Pharma Inc. (LTRN) and Salarius Pharmaceuticals Inc. (SLRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LTRN and SLRX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LTRN is the larger of the two at $40.6M, about 2.1x SLRX ($19.4M).
- Over the past year, LTRN is up 11.9% and SLRX is down 92.7% - LTRN leads by 104.5 points.
- LTRN has hit the wire 4 times in the past 4 weeks while SLRX has been quiet.
- LTRN has more recent analyst coverage (3 ratings vs 2 for SLRX).
- Company
- Lantern Pharma Inc.
- Salarius Pharmaceuticals Inc.
- Price
- $3.72+5.38%
- $0.82+36.55%
- Market cap
- $40.6M
- $19.4M
- 1M return
- +81.02%
- -3.57%
- 1Y return
- +11.88%
- -92.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 4
- 0
- Recent ratings
- 3
- 2
Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.
Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
Latest LTRN
- Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
- Lantern Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form D filed by Lantern Pharma Inc.
- Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
- Lantern Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Lantern Pharma Inc.
- Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
- Lantern Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
- Director Keyser D Jeffrey bought $100,001 worth of shares (48,544 units at $2.06), increasing direct ownership by 106% to 94,303 units (SEC Form 4)
- Director Schalop Lee Troy bought $100,001 worth of shares (48,544 units at $2.06) (SEC Form 4)
Latest SLRX
- SEC Form DEF 14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Director Hanish Arnold C sold $17 worth of shares (27 units at $0.64), closing all direct ownership in the company (SEC Form 4)
- SEC Form 8-K filed by Salarius Pharmaceuticals Inc.
- SEC Form PRE 14A filed by Salarius Pharmaceuticals Inc.
- SEC Form DEFA14A filed by Salarius Pharmaceuticals Inc.
- Salarius Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting